AstraZeneca has revealed the proposed designs for its new global R&D centre and corporate headquarters in Cambridge in the UK. The unveiling of the plans for an ambitious, purpose built ...

Construction of AstraZeneca’s new global and R&D headquarters in Cambridge should have been completed last autumn – but builders are struggling to meet a revised deadline of May 2019.

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

The Cambridge Biomedical Campus – already the largest centre of medical research and health science in Europe – could double ...

The duality is a hallmark of Greater Boston’s lab market these days. Bright spots surely remain, such as big new lab ...

Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

Multinational pharmaceutical company AstraZeneca said on Monday that Shanghai will be ... Following the four strategic centers in the UK's Cambridge, Boston and Gaithersburg in the United States, and ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

HEADQUARTERS IN ROCKVILLE. THIS LAB ISN’T OPEN OR OPERATIONAL YET, BUT ONCE IT IS, THE FOLKS AT ASTRAZENECA BELIEVE IT IS GOING TO REVOLUTIONIZE CANCER TREATMENT. IT GIVES US HOPE. I MEAN.

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non ...

AstraZeneca recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer.